JO3483B1 - 4-هيدروكسي -2- مثيل -5- (بروبان-2-يليدين) هكس - 3- ين حلقي كربالدهيد للوقاية من ومعالجة مرض معرفي أو تنكسي عصبي أو عصبي - Google Patents
4-هيدروكسي -2- مثيل -5- (بروبان-2-يليدين) هكس - 3- ين حلقي كربالدهيد للوقاية من ومعالجة مرض معرفي أو تنكسي عصبي أو عصبيInfo
- Publication number
- JO3483B1 JO3483B1 JOP/2013/0390A JOP20130390A JO3483B1 JO 3483 B1 JO3483 B1 JO 3483B1 JO P20130390 A JOP20130390 A JO P20130390A JO 3483 B1 JO3483 B1 JO 3483B1
- Authority
- JO
- Jordan
- Prior art keywords
- neurodegenerative
- cognitive
- prevention
- treatment
- enecarbaldehyde
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000001149 cognitive effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000001537 neural effect Effects 0.000 title abstract 2
- 230000000626 neurodegenerative effect Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- NESSRRDBNBBGEK-UHFFFAOYSA-N 4-hydroxy-2-methyl-5-propan-2-ylidenecyclohex-3-ene-1-carbaldehyde Chemical compound CC1C=C(O)C(=C(C)C)CC1C=O NESSRRDBNBBGEK-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
- C07C47/46—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing hydroxy groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
مركب صيدلي يستخدم في الوقاية من ومعالجة اضطراب أو مرض معرفي أو تنكسي عصبي أو عصبي الملخص يتعلق الاختراع الراهن بمركب صيدلي له الصيغة (1): الصيغة (1) أو ملح مقبول صيدلياً منه، يستخدم في الوقاية من ومعالجة اضطراب أو مرض معرفي أو تنكسي عصبي أو عصبي ، مثل مرض الزهايمر، تركيب صيدلي وطريقة لتحضير تركيب صيدلي.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU92126A LU92126B1 (fr) | 2012-12-31 | 2012-12-31 | Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3483B1 true JO3483B1 (ar) | 2020-07-05 |
Family
ID=47470067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2013/0390A JO3483B1 (ar) | 2012-12-31 | 2013-12-30 | 4-هيدروكسي -2- مثيل -5- (بروبان-2-يليدين) هكس - 3- ين حلقي كربالدهيد للوقاية من ومعالجة مرض معرفي أو تنكسي عصبي أو عصبي |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US9284250B2 (ar) |
| EP (1) | EP2938337A1 (ar) |
| JP (1) | JP6699961B2 (ar) |
| KR (1) | KR102104155B1 (ar) |
| CN (1) | CN104884052B (ar) |
| AR (1) | AR094318A1 (ar) |
| AU (1) | AU2013369491B2 (ar) |
| BR (1) | BR112015015509B1 (ar) |
| CA (1) | CA2895429C (ar) |
| CL (1) | CL2015001881A1 (ar) |
| EA (1) | EA029650B1 (ar) |
| HK (1) | HK1214517A1 (ar) |
| IL (1) | IL239622B (ar) |
| JO (1) | JO3483B1 (ar) |
| LU (1) | LU92126B1 (ar) |
| MA (1) | MA38307B1 (ar) |
| MX (1) | MX369590B (ar) |
| MY (1) | MY171832A (ar) |
| NZ (1) | NZ710131A (ar) |
| PE (1) | PE20151424A1 (ar) |
| PH (1) | PH12015501402B1 (ar) |
| SG (1) | SG11201504744WA (ar) |
| TN (1) | TN2015000275A1 (ar) |
| TW (1) | TWI590819B (ar) |
| UA (1) | UA117822C2 (ar) |
| UY (1) | UY35253A (ar) |
| WO (1) | WO2014102090A1 (ar) |
| ZA (1) | ZA201505057B (ar) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110684067A (zh) | 2012-12-21 | 2020-01-14 | 艾丽奥斯生物制药有限公司 | 取代的核苷和核苷酸 |
| MY199866A (en) * | 2017-01-13 | 2023-11-26 | Bened Biomedical Co Ltd | A novel lactic acid bacteria and its applications |
| KR102017415B1 (ko) * | 2018-02-13 | 2019-09-02 | 연세대학교 산학협력단 | 뇌 신경 손상 완화용 조성물 |
| CN108813453A (zh) * | 2018-05-23 | 2018-11-16 | 青岛大学 | 一种防治帕金森病的食用组合物 |
| JP7329140B2 (ja) | 2019-12-02 | 2023-08-17 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | トラフを有するシーシャ装置 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001068576A1 (en) * | 2000-03-10 | 2001-09-20 | Applied Genetics Incorporated Dermatics | Dermatological compounds |
| CN1511520A (zh) * | 2002-12-31 | 2004-07-14 | �й�ҽѧ��ѧԺҩ���о��� | 丁二酸酯衍生物治疗痴呆症的用途 |
| EP1605940A1 (en) * | 2003-03-14 | 2005-12-21 | Merck Sharp & Dohme Ltd. | METHOD FOR TREATING MILD COGNITIVE IMPAIRMENT AND FOR PREVENTING OR DELAYING ALZHEIMER’S DISEASE |
-
2012
- 2012-12-31 LU LU92126A patent/LU92126B1/fr active
-
2013
- 2013-12-17 CN CN201380069044.3A patent/CN104884052B/zh active Active
- 2013-12-17 MX MX2015008520A patent/MX369590B/es active IP Right Grant
- 2013-12-17 NZ NZ710131A patent/NZ710131A/en unknown
- 2013-12-17 US US14/758,343 patent/US9284250B2/en active Active
- 2013-12-17 UA UAA201507037A patent/UA117822C2/uk unknown
- 2013-12-17 EP EP13808014.8A patent/EP2938337A1/en not_active Ceased
- 2013-12-17 BR BR112015015509-0A patent/BR112015015509B1/pt active IP Right Grant
- 2013-12-17 AU AU2013369491A patent/AU2013369491B2/en active Active
- 2013-12-17 JP JP2015550024A patent/JP6699961B2/ja active Active
- 2013-12-17 PE PE2015001180A patent/PE20151424A1/es unknown
- 2013-12-17 MA MA38307A patent/MA38307B1/fr unknown
- 2013-12-17 CA CA2895429A patent/CA2895429C/en active Active
- 2013-12-17 MY MYPI2015702083A patent/MY171832A/en unknown
- 2013-12-17 EA EA201591021A patent/EA029650B1/ru unknown
- 2013-12-17 KR KR1020157020805A patent/KR102104155B1/ko active Active
- 2013-12-17 HK HK16102495.8A patent/HK1214517A1/zh unknown
- 2013-12-17 SG SG11201504744WA patent/SG11201504744WA/en unknown
- 2013-12-17 WO PCT/EP2013/076936 patent/WO2014102090A1/en not_active Ceased
- 2013-12-27 AR ARP130105072A patent/AR094318A1/es not_active Application Discontinuation
- 2013-12-30 UY UY0001035253A patent/UY35253A/es not_active Application Discontinuation
- 2013-12-30 TW TW102148993A patent/TWI590819B/zh active
- 2013-12-30 JO JOP/2013/0390A patent/JO3483B1/ar active
-
2015
- 2015-06-16 TN TNP2015000275A patent/TN2015000275A1/fr unknown
- 2015-06-18 PH PH12015501402A patent/PH12015501402B1/en unknown
- 2015-06-24 IL IL239622A patent/IL239622B/en active IP Right Grant
- 2015-06-30 CL CL2015001881A patent/CL2015001881A1/es unknown
- 2015-07-14 ZA ZA2015/05057A patent/ZA201505057B/en unknown
-
2016
- 2016-03-14 US US15/069,118 patent/US9611205B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ712207A (en) | Tetrahydropyrrolothiazine compounds | |
| IN2014DN10670A (ar) | ||
| NZ779654A (en) | Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs | |
| PT2892563T (pt) | Composições farmacêuticas para tratar a doença de alzheimer | |
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MX2013011589A (es) | Metodos y composiciones para tratar enfermedad de parkinson. | |
| MX2009010407A (es) | Derivados fluorados de deferiprona. | |
| TN2015000018A1 (en) | 5-ht3 receptor antagonists | |
| EP2416795A4 (en) | COGNITIVE DECLINE INHIBITORS | |
| IN2015DN01023A (ar) | ||
| WO2013040227A3 (en) | Therapeutic compounds | |
| MX2015000618A (es) | Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas. | |
| PH12015501402A1 (en) | 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease | |
| PH12016502568A1 (en) | Novel heterocyclic compound | |
| HK1202452A1 (en) | Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation | |
| MX2016008968A (es) | Compuestos organicos. | |
| MX2015008292A (es) | Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
| WO2015189830A9 (en) | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease | |
| GB201206984D0 (en) | New therapeutic use | |
| IN2013MU03838A (ar) | ||
| WO2013121334A3 (en) | Agents for treating neurodegenerative disorders | |
| HK1202249A1 (en) | Vesicular formulations |